Shots:

• The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab- 1mg/kg) + Yervoy (ipilimumab- 3mg/kg) in patients with mCRPC
• P-II study result in asymptomatic or minimally symptomatic patients & patients who progressed after taxane-based CT ORR @ 11.9/13.5 mos. (25%- 10%); GRADE 3AEs or 5AEs (42%- 53%)- Presented at ASCO 2019
• Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US- EU- Japan & China

Ref: BMS | Image: BMS